Frequently Asked
Questions.

Iris Vitality welcomes all genders. To utilize our clinical pathways, you must be over 21, reside in or be located in a state where our services are authorized, and have a medically justified need for treatment.

Iris Vitality is dedicated to transforming healthcare access through innovative telehealth solutions. We prioritize immediate, inclusive, and transparent care, eliminating waitlists and tackling high medication costs.

Yes. All medical providers in our network are US-based, Board-Certified physicians. All medications are fulfilled by state-licensed sterile compounding pharmacies located within the United States.

We provide a streamlined telehealth experience. Begin by completing a medical intake form. A US-licensed physician will review your markers, and if appropriate, your medication will be authorized and shipped directly to you every 30, 60, or 90 days.

No, our providers review your information entirely online through our secure portal. If prescribed, you’ll have unlimited access to message your care team for follow-ups and titration questions.

No. Simply inform your clinical provider about your previous titration history, and we can facilitate continuity at the appropriate dosage level based on medical necessity.

We specialize in authorising Semaglutide or Tirzepatide protocols. These are clinical-grade GLP-1 and GIP agonists customized to your unique biological health profile.

GLP-1 is a hormone that regulates blood sugar and appetite. Our protocols mimic these naturally occurring hormones to reset your metabolic biological set point.

Semaglutide mimics GLP-1 to control hunger; Tirzepatide is a dual-agonist mimicking both GLP-1 and GIP for a more robust biological reset.

Common effects include nausea, fatigue, or mild GI adjustments. Our providers manage titration carefully. See the official FDA label for info.

Clinical trials show ~15% weight reduction for semaglutide and ~22.5% for tirzepatide over 12 months. Results vary based on metabolism.

This depends on your metabolic goals. We transition patients through titration, momentum, and maintenance phases for long-term stability.

Our clinicians authorize a protocol based on history. Semaglutide is a standard single-pathway agonist; Tirzepatide is a dual-pathway agonist.

All protocols are fulfilled exclusively by U.S. State Board of Pharmacy licensed pharmacies under rigorous sterile compounding standards.